Literature DB >> 12911632

Hydrogen peroxide induces loss of dopamine transporter activity: a calcium-dependent oxidative mechanism.

Chuen-Lin Huang1, Nai-Kuei Huang, Song-Kun Shyue, Yijuang Chern.   

Abstract

H2O2 dose dependently inhibited dopamine uptake in PC12 cells and in striatal synaptosomes. Treatment with H2O2 resulted in a reversible reduction in Vmax, with no effect on its Km value. This suppressive effect of H2O2 could be relieved by reducing agents (dithiothreitol and cysteine). Furthermore, an oxidizer (dithiodipyridine) also markedly suppressed the dopamine transporter (DAT). Oxidative stress therefore might contribute to the action of H2O2. H2O2 appeared to modify DAT at both extracellular and intracellular sites because cumene-H2O2 (a radical generator mostly restricted to plasma membranes) at high concentrations also slightly suppressed DAT activity and the intracellular overexpression of catalase ameliorated the inhibitory effect of H2O2. Internalization was unlikely to be involved because concanavalin A, which blocked endocytosis, did not prevent the H2O2-evoked inhibition of DAT activity. Interestingly, H2O2 treatment evoked a Ca2+ influx in PC12 cells. Moreover, removal of external calcium by EGTA or reduction in the intracellular calcium level using BAPTA-AM reversed the inhibitory effect of H2O2. Conversely, depletion of intracellular calcium stores using thapsigargin did not affect the reduction in DAT activity by H2O2. Collectively, our results indicate that the DAT, one of the most important proteins controlling the dopaminergic system, is also a redox sensor. In addition, H2O2 might suppress the DAT by a Ca2+-dependent oxidative pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911632     DOI: 10.1046/j.1471-4159.2003.01936.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Mikhail V Pletnikov; Elizabeth L Engle; Patrick M Tarwater; David R Graham; M Christine Zink
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-27       Impact factor: 4.147

2.  Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system.

Authors:  Jaime M Hatcher; Jason R Richardson; Thomas S Guillot; Alison L McCormack; Donato A Di Monte; Dean P Jones; Kurt D Pennell; Gary W Miller
Journal:  Exp Neurol       Date:  2007-01-05       Impact factor: 5.330

3.  Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Authors:  Gregory C Hadlock; Anthony J Baucum; Jill L King; Kristen A Horner; Glen A Cook; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

Review 4.  Dopamine and aging: intersecting facets.

Authors:  C David Rollo
Journal:  Neurochem Res       Date:  2008-10-08       Impact factor: 3.996

5.  Quantitation of hydrogen peroxide fluctuations and their modulation of dopamine dynamics in the rat dorsal striatum using fast-scan cyclic voltammetry.

Authors:  Marina Spanos; Julie Gras-Najjar; Jeremy M Letchworth; Audrey L Sanford; J Vincent Toups; Leslie A Sombers
Journal:  ACS Chem Neurosci       Date:  2013-04-24       Impact factor: 4.418

6.  Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats.

Authors:  Roselei Fachinetto; Jardel G Villarinho; Caroline Wagner; Romaiana P Pereira; Robson L Puntel; Márcio W Paixão; Antonio L Braga; João Batista Calixto; João B T Rocha; Juliano Ferreira
Journal:  Psychopharmacology (Berl)       Date:  2007-07-20       Impact factor: 4.530

7.  Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels.

Authors:  I A Reddy; J A Pino; P Weikop; N Osses; G Sørensen; T Bering; C Valle; R J Bluett; K Erreger; G Wortwein; J G Reyes; D Graham; G D Stanwood; T A Hackett; S Patel; A Fink-Jensen; G E Torres; A Galli
Journal:  Transl Psychiatry       Date:  2016-05-17       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.